Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.
Klinman
D M
DM
Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Kamstrup
S
S
Verthelyi
D
D
Gursel
I
I
Ishii
K J
KJ
Takeshita
F
F
Gursel
M
M
D000276:Adjuvants, Immunologic / Q000633:toxicity; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001428:Bacterial Vaccines / Q000276:immunology / Q000633:toxicity; D002986:Clinical Trials as Topic; D018899:CpG Islands / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis*; D004269:DNA, Bacterial / Q000276:immunology* / Q000494:pharmacology / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D005604:Francisella tularensis / Q000276:immunology; D005688:Galactosamine / Q000633:toxicity; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D007075:Immunoglobulin M / Q000096:biosynthesis*; D017053:Infection Control; D008070:Lipopolysaccharides / Q000633:toxicity; D008089:Listeria monocytogenes / Q000276:immunology; D008088:Listeriosis / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009838:Oligodeoxyribonucleotides / Q000138:chemical synthesis / Q000276:immunology / Q000494:pharmacology; D012449:Safety; D014406:Tularemia / Q000517:prevention & control; D019444:Vaccines, DNA / Q000276:immunology / Q000633:toxicity; D014614:Vaccines, Synthetic / Q000276:immunology / Q000633:toxicity
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D016207:Cytokines; D004269:DNA, Bacterial; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D009838:Oligodeoxyribonucleotides; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D005688:Galactosamine